Niagen Bioscience (NAGE) Long-Term Investments (2013 - 2016)

Niagen Bioscience (NAGE) reported Long-Term Investments of $20318.0 for Q4 2016, little changed quarter-over-quarter from $20318.0 in Q4 2016.

Niagen Bioscience (NAGE) Long-Term Investments (2013 - 2016) Analysis & Trends

Niagen Bioscience (NAGE) has 2 years of Long-Term Investments data on file, last reported at $20318.0 in Q4 2016.

Long-Term Investments for Q4 2016 came in at $20318.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $20318.0 (changed N/A YoY), and the FY2016 annual result was $20318.0, changed N/A from the prior year.
Long-Term Investments held at $20318.0 in Q4 2016 per NAGE's latest filing, from $20318.0 in the prior quarter.
Over five years, Long-Term Investments peaked at $2.7 million in Q1 2013 and troughed at $20318.0 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	5.75 Bn
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Niagen Bioscience	269.32 Mn	202.77 Mn	19.98 Mn	-

Download Data